A Phase 1, Open-label, 2-cohort, Multiple Dose, Drug-drug Interaction, Safety and Tolerability, Fixed-sequence Study to Investigate the Potential Interaction Between ATI-2173 When Coadministered With Tenofovir Disoproxil Fumarate in Healthy Subjects
Latest Information Update: 07 Feb 2022
At a glance
- Drugs ATI-2173 (Primary) ; Tenofovir disoproxil fumarate (Primary)
- Indications Hepatitis B; Hepatitis D
- Focus Pharmacokinetics
- Sponsors Antios Therapeutics
- 03 Feb 2022 Status changed from recruiting to completed.
- 16 Dec 2021 Planned primary completion date changed from 1 Dec 2021 to 31 Dec 2021.
- 03 Dec 2021 New trial record